EICHOR
● Active Not Recruiting
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
Condition: Rejection; Transplant, Liver · Liver Failure · Liver Diseases · Sponsor: Quell Therapeutics Limited
About this study
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (10)
| H. Saint Luc | Brussels, Belgium | — |
| Hopital Erasme | Brussels, Belgium | — |
| UZ Leuven | Leuven, Belgium | — |
| H. Clinic Barcelona | Barcelona, Spain | — |
| Hospital Reina Sofia | Córdoba, Spain | — |
| G. Gergorio Maranon | Madrid, Spain | — |
| Queen Elizabeth Hospital | Birmingham, United Kingdom | — |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge, United Kingdom | — |
| Royal Free London NHS Foundation Trust | London, United Kingdom | — |
| King's College Hospital NHS Foundation Trust | London, United Kingdom | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05234190